1
|
Lee MR, Lai CL, Chan KA. Intensive Care Unit Admission and Survival in Stage IV Cancer Patients with Septic Shock: A Population-Based Cohort Study. J Cancer 2019; 10:3179-3187. [PMID: 31289588 PMCID: PMC6603387 DOI: 10.7150/jca.30278] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2018] [Accepted: 04/15/2019] [Indexed: 01/06/2023] Open
Abstract
Background: The impact of intensive care unit (ICU) admission during life-threatening critical illness on survival of patients with advanced cancer remains unknown. Methods: We identified incident stage IV cancer patients from Taiwan Cancer Registry during 2009-2013 and ascertained the first episode of septic shock after cancer diagnosis. Patient was classified as ICU admission and no ICU admission during the index hospitalization. Primary outcome of interest was overall survival. Propensity score (PS) and proportional hazards regression were used to control potential confounders. Results: A total of 11,825 stage IV cancer patients with septic shock were identified. Among them, 6,089 (51.5%) patients were admitted to ICU during the index hospitalization and 3,626 (30.7%) patients survived the index hospitalization. A 1:1 propensity score (PS)-matched cohort of 7,186 patients were created for patients with/without ICU admission among the total study population. Both the PS-stratified analysis among the overall population (pooled hazard ratio [HR]: 0.78, 95% confidence interval [CI]: 0.74-0.81) and analysis among the PS-matched population (HR: 0.76, 95% CI: 0.72-0.79) showed association between ICU admission and better overall survival. ICU admission was also associated with a lower risk of in-hospital mortality in both PS-stratified analysis (pooled odds ratio [OR]: 0.69, 95% CI: 0.63-0.75) and PS-matched analysis (OR: 0.61, 95% CI: 0.55-0.68). In PS-stratified analysis for long-term survival after discharge among hospital survivors, ICU admission was associated with improved long-term survival after discharge (pooled HR: 0.73, 95% CI: 0.68-0.80). Also ICU admission was associated with better long-term survival after discharge (HR: 0.77, 95% CI: 0.70-0.85) in PS-matched analysis. Conclusions: Though ICU admission with aggressive treatment may be associated with improved survival, the majority (70%) of stage IV cancer patients with septic shock were unable to survive until hospital discharge.
Collapse
Affiliation(s)
- Meng-Rui Lee
- Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.,Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.,Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Chao-Lun Lai
- Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.,Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.,Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.,Center for Critical Care Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan
| | - K Arnold Chan
- Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.,Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
| |
Collapse
|
2
|
Initial and late efficacy of everolimus-eluting stents for small and non-small coronary lesions from evaluating delayed late loss study. Heart Vessels 2017; 32:1415-1423. [PMID: 28687988 DOI: 10.1007/s00380-017-1018-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2016] [Accepted: 06/30/2017] [Indexed: 10/19/2022]
Abstract
The aim of the present study was to evaluate the long-term outcomes at 2 years in patients in whom everolimus-eluting stents (EESs) were implanted in small and non-small vessels. A small vessel is an important risk factor for restenosis with BMSs, even in the first generation DESs. The 690 patients with 690 lesions implanted with an EES were enrolled and divided into two groups by vessel reference diameter (RD): >2.5 mm for non-small vessels (Non-S-group) and ≤2.5 mm for small vessels (S-group). Two years later, the 365 patients with no restenosis at 8 months who underwent angiography were enrolled into the late catch-up study. At the initial 8-month follow-up, the rates of restenosis and target lesion revascularization (TLR) of both groups were not significantly different (restenosis 3.9 vs 6.5%, p = 0.17; TLR 3.9 vs 6.5%, p = 0.17). At the late 2-year follow-up, there were no significant differences in the late loss (0.36 ± 0.66 vs 0.34 ± 0.50 mm, p = 0.14), net gain (1.50 ± 0.75 vs 1.26 ± 0.60 mm, p = 0.39), late catch-up restenosis rate (5.1 vs 3.4%, p = 0.38), TLR (4.9 vs 2.7%, p = 0.40), and delayed late loss (0.14 ± 0.58 vs 0.15 ± 0.49 mm, p = 0.10) between both groups. There is no correlation between delayed late loss and RD in all patients(r = -0.009) and in AMI patients (r = -0.004). These results demonstrate that the initial and late catch-up restenosis rates of small coronary vessels with EES placement were excellent, the same as for non-small coronary vessels. We suggest that involvement of small coronary arteries may not be a risk factor for restenosis and results of stenting for small coronary arteries with EES placement were excellent.
Collapse
|
4
|
Lai CL, Kuo RNC, Chen HM, Chen MF, Chan KA, Lai MS. Risk of ischemic stroke during the initiation period of α-blocker therapy among older men. CMAJ 2015; 188:255-260. [PMID: 26644502 DOI: 10.1503/cmaj.150624] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/26/2015] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Alpha-blockers are notorious for their first-dose effect of acute hypotension during the early initiation period. Because acute cerebral hypoperfusion may precipitate an episode of ischemic stroke, we aimed to provide a quantitative estimate of the risk of ischemic stroke during the early initiation period of α-blocker therapy, using a self-controlled case series design. METHODS We identified all men aged 50 years or more as of 2007 who were incident users of α-blockers and had a diagnosis of ischemic stroke during the 2007-2009 study period using claims data from Taiwan's National Health Insurance claims database. The first day on which the α-blocker was prescribed was the index date. We partitioned different risk periods according to their relationship to the index date (pre-exposure risk periods 1 and 2 = ≤ 21 d and 22-60 d before index date, respectively; post-exposure risk periods 1 and 2 = ≤ 21 d and 22-60 d after index date, respectively); the remainder of the study period was defined as the unexposed period. We estimated the incidence rate ratio (IRR) of ischemic stroke in each risk period relative to the unexposed period using a conditional Poisson regression model. RESULTS A total of 7502 men were included. Compared with the risk in the unexposed period, the risk of ischemic stroke was increased in post-exposure risk period 1 among all patients in the study population (adjusted IRR 1.40, 95% confidence interval [CI], 1.22-1.61) and among patients without concomitant prescriptions for other antihypertensive agents (adjusted IRR 2.11, 95% CI 1.73-2.57). INTERPRETATION Alpha-blocker therapy was associated with an increased risk of ischemic stroke during the early initiation period, especially among patients who were not taking other antihypertensive agents.
Collapse
Affiliation(s)
- Chao-Lun Lai
- Department of Internal Medicine and Center for Critical Care Medicine (C.-L. Lai), National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan; Department of Internal Medicine (C.-L. Lai), National Taiwan University College of Medicine, Taipei, Taiwan; Institute of Epidemiology and Preventive Medicine (C.-L. Lai, M.-S. Lai) and Institute of Health Policy and Management (Kuo), College of Public Health, National Taiwan University, Taipei, Taiwan; Center for Comparative Effectiveness Research (Kuo, H.-M. Chen, M.-S. Lai), National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan; Departments of Internal Medicine (M.-F. Chen) and Medical Research (Chan), National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology (Chan), National Taiwan University College of Medicine, Taipei, Taiwan
| | - Raymond Nien-Chen Kuo
- Department of Internal Medicine and Center for Critical Care Medicine (C.-L. Lai), National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan; Department of Internal Medicine (C.-L. Lai), National Taiwan University College of Medicine, Taipei, Taiwan; Institute of Epidemiology and Preventive Medicine (C.-L. Lai, M.-S. Lai) and Institute of Health Policy and Management (Kuo), College of Public Health, National Taiwan University, Taipei, Taiwan; Center for Comparative Effectiveness Research (Kuo, H.-M. Chen, M.-S. Lai), National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan; Departments of Internal Medicine (M.-F. Chen) and Medical Research (Chan), National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology (Chan), National Taiwan University College of Medicine, Taipei, Taiwan
| | - Ho-Min Chen
- Department of Internal Medicine and Center for Critical Care Medicine (C.-L. Lai), National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan; Department of Internal Medicine (C.-L. Lai), National Taiwan University College of Medicine, Taipei, Taiwan; Institute of Epidemiology and Preventive Medicine (C.-L. Lai, M.-S. Lai) and Institute of Health Policy and Management (Kuo), College of Public Health, National Taiwan University, Taipei, Taiwan; Center for Comparative Effectiveness Research (Kuo, H.-M. Chen, M.-S. Lai), National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan; Departments of Internal Medicine (M.-F. Chen) and Medical Research (Chan), National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology (Chan), National Taiwan University College of Medicine, Taipei, Taiwan
| | - Ming-Fong Chen
- Department of Internal Medicine and Center for Critical Care Medicine (C.-L. Lai), National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan; Department of Internal Medicine (C.-L. Lai), National Taiwan University College of Medicine, Taipei, Taiwan; Institute of Epidemiology and Preventive Medicine (C.-L. Lai, M.-S. Lai) and Institute of Health Policy and Management (Kuo), College of Public Health, National Taiwan University, Taipei, Taiwan; Center for Comparative Effectiveness Research (Kuo, H.-M. Chen, M.-S. Lai), National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan; Departments of Internal Medicine (M.-F. Chen) and Medical Research (Chan), National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology (Chan), National Taiwan University College of Medicine, Taipei, Taiwan
| | - K Arnold Chan
- Department of Internal Medicine and Center for Critical Care Medicine (C.-L. Lai), National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan; Department of Internal Medicine (C.-L. Lai), National Taiwan University College of Medicine, Taipei, Taiwan; Institute of Epidemiology and Preventive Medicine (C.-L. Lai, M.-S. Lai) and Institute of Health Policy and Management (Kuo), College of Public Health, National Taiwan University, Taipei, Taiwan; Center for Comparative Effectiveness Research (Kuo, H.-M. Chen, M.-S. Lai), National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan; Departments of Internal Medicine (M.-F. Chen) and Medical Research (Chan), National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology (Chan), National Taiwan University College of Medicine, Taipei, Taiwan
| | - Mei-Shu Lai
- Department of Internal Medicine and Center for Critical Care Medicine (C.-L. Lai), National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan; Department of Internal Medicine (C.-L. Lai), National Taiwan University College of Medicine, Taipei, Taiwan; Institute of Epidemiology and Preventive Medicine (C.-L. Lai, M.-S. Lai) and Institute of Health Policy and Management (Kuo), College of Public Health, National Taiwan University, Taipei, Taiwan; Center for Comparative Effectiveness Research (Kuo, H.-M. Chen, M.-S. Lai), National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan; Departments of Internal Medicine (M.-F. Chen) and Medical Research (Chan), National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology (Chan), National Taiwan University College of Medicine, Taipei, Taiwan
| |
Collapse
|
5
|
Lin L, Jin C, Wei X, Li H, Shi J, Wu S, Yang X, Qi X. Comparison on the efficacy of everolimus-eluting stent and zotarolimus-eluting stents in coronary heart disease between diabetic and non-diabetic patients. Int J Clin Exp Med 2015; 8:20813-20820. [PMID: 26885005 PMCID: PMC4723850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2015] [Accepted: 09/02/2015] [Indexed: 06/05/2023]
Abstract
OBJECTIVE The aim of this study is to examine and compare the efficacy of everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in coronary heart disease in diabetic or non-diabetic patients. METHODS A total of 666 patients needed for percutaneous coronary intervention were randomly selected from June 2008 to June 2013 in our hospital and were divided into two groups: (i) coronary heart disease with diabetes group and (ii) non-diabetes group. Patients in each group were further assigned to receive treatment of either EES or ZES. Then we observed the major adverse cardiac events, including mortality, nonfatal myocardial infarction and non-fatal cerebrovascular events over the period of 15 months after initial stent implantation. RESULTS Compared to the non-diabetic group, more patients in diabetic group had received anti-hypotensive treatment (72% vs. 49%, P < 0.0001) and hypolipemic treatment (80% vs. 67%, P < 0.0001) before the percutaneous coronary intervention. In both diabetic group and non-diabetic group, patients received ZES treatment had a much greater incidence rate of major adverse cardiac events compared to the patients received EES treatment (P < 0.05). Meanwhile, target lesion revascularization rate in the ZES group was also significantly higher than that in the EES group. The data showed big differences between ZES and EES groups with important statistical significance (P < 0.05). CONCLUSION Patients with coronary heart disease and diabetes have a higher risk of major adverse cardiac events after stent implantation. EES treatment is safer with higher efficacy in our study, being a more effective stent for the patients merged with diabetes.
Collapse
Affiliation(s)
- Liming Lin
- Tianjin Teda International Cardiovascular Hospital, Cardiovascular Clinical Hospital, Tianjin Medical University61 Third Street, Tianjin Economic and Technological Development Area, Tianjin 300070, P. R. China
- Tangshan Kailuan General Hospital57 East Xinhua Street, Tangshan 063000, Hebei Province, P. R. China
| | - Cheng Jin
- Tangshan Kailuan General Hospital57 East Xinhua Street, Tangshan 063000, Hebei Province, P. R. China
| | - Xiaoming Wei
- Tangshan Kailuan General Hospital57 East Xinhua Street, Tangshan 063000, Hebei Province, P. R. China
| | - Huiying Li
- Tangshan Kailuan General Hospital57 East Xinhua Street, Tangshan 063000, Hebei Province, P. R. China
| | - Jihong Shi
- Tangshan Kailuan General Hospital57 East Xinhua Street, Tangshan 063000, Hebei Province, P. R. China
| | - Shouling Wu
- Tangshan Kailuan General Hospital57 East Xinhua Street, Tangshan 063000, Hebei Province, P. R. China
| | - Xiaojie Yang
- Tangshan Maternal and Child Health HospitalTangshan 063000, Hebei Province, P. R. China
| | - Xiangqian Qi
- Tianjin Teda International Cardiovascular Hospital, Cardiovascular Clinical Hospital, Tianjin Medical University61 Third Street, Tianjin Economic and Technological Development Area, Tianjin 300070, P. R. China
| |
Collapse
|